Seven new drugs are expected to reach $1 billion in annual revenue in the next five years, according to a report issued Jan. 10 by analytics firm Clarivate.

Six of the drugs are awaiting FDA approval, and one (tezepelumab) just won approval. Here is a list:

Search form

You are here

7 drugs likely to hit $1B in annual revenue in the next 5 years

7 drugs likely to hit $1B in annual revenue in the next 5 years